The CXCR5 receptor, a new target in inflammation?

Abstract

A method of treating CXCL13-mediated inflammatory diseases by the co-administration of a CXCL13 antagonist and a TNF-α antagonist is claimed. Their use is claimed to provide methods of treating asthma, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis and systemic lupus erythematosus. The reported activity of such combinations in animal models provides evidence for the CXCR5 chemokine receptor as a potential drug target in such diseases.

Keywords::

• asthma
• chemokine
• COPD
• CXCL13
• CXCR5
• inflammation
• lupus
• pulmonary fibrosis